Valuation : Interpace Biosciences, Inc.

Market Cap 42.21M 36.44M 34.16M 31.18M 58.67M 4.03B 58.95M 405M 158M 2.04B 158M 155M 6.75B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 40.88M 35.3M 33.09M 30.21M 56.83M 3.9B 57.11M 392M 153M 1.97B 153M 150M 6.54B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day+5.08%
1 week+0.05%
Current month+0.44%
1 month-1.81%
3 months-10.38%
6 months-14.60%
Current year+23.85%
1 week 6.5
Extreme 6.5
7.85
1 month 6.5
Extreme 6.5
8.5
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
51.65
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap.
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Fiscal year

Chief Financial Officer

1,385,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
+5.08%+0.05%+83.02%+26.97% 42.21M
-3.67%-1.74%+93.91%+483.75% 47.03B
-0.21%-0.37%+20.55%+58.57% 27.18B
-0.30%-4.93%-16.15%-37.78% 7.1B
-1.00%-2.88%+3.97%+128.37% 5.87B
-0.27%+1.95%+16.22%+76.62% 3.38B
-3.26%-0.84%-33.33%+1,797.47% 2.57B
-3.17%+6.30%+105.58%+25.00% 2.32B
+1.02%+1.02%+29.25%+25.80% 1.97B
-1.93%-12.54%-14.69%-54.48% 1.89B
Average -0.77%-0.92%+28.83%+253.03% 9.94B
Weighted average by Cap. -2.06%-1.38%+51.64%+299.15%

Financials

2024 2025
Net sales 46.93M 40.51M 37.98M 34.67M 65.23M 4.48B 65.55M 450M 176M 2.26B 176M 172M 7.51B 38.73M 33.44M 31.34M 28.62M 53.84M 3.69B 54.1M 371M 145M 1.87B 145M 142M 6.2B
Net income 6.7M 5.79M 5.42M 4.95M 9.32M 639M 9.36M 64.28M 25.1M 323M 25.16M 24.61M 1.07B 24.58M 21.22M 19.89M 18.16M 34.16M 2.34B 34.33M 236M 92.03M 1.19B 92.26M 90.25M 3.93B
Net Debt 4.4M 3.79M 3.56M 3.25M 6.11M 419M 6.14M 42.16M 16.46M 212M 16.5M 16.14M 703M -1.32M -1.14M -1.07M -977K -1.84M -126M -1.85M -12.68M -4.95M -63.76M -4.96M -4.86M -212M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
28/08/26 $7.618 +5.08% 2,520
26/08/26 $7.250 +2.11% 1,420
25/08/26 $7.100 -0.70% 1,299
24/08/26 $7.150 -6.09% 402
21/08/26 $7.614 -5.42% 1,965

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXG.D Stock